An assets sale is tipped as the next move for the embattled pathology provider.
An assets sale is tipped as the next move for the embattled pathology provider.
End of content
No more pages to load
From The Source
- How invisible medical groups are powering telehealth’s GLP-1 ‘gold rush’
- Orthocell quarterly report
- Australian Government response to the Mental Health and Suicide Prevention – Final Report
- Australian Government response to the Inquiry into childhood rheumatic diseases – Interim Report
- 2024 Victorian Honour Roll of Women inductees announced
- Union calls for penalties for workers to be scrapped from Aged Care Act – Health Services Union
- VAHI: MH and AoD treatment services in Victoria
- DoHAC: Restrictive practices in aged care – a last resort
- Nyrada gears up for Phase I clinical trials
- Rats – and investors – are happy as Nyrada forges ahead with its first human trial
- Radiopharm Theranostics (ASX:RAD): Fireside Chat with CEO Riccardo Canevari
- Neuren Pharmaceuticals: DAYBUE™ (trofinetide) receives marketing authorization in Canada